CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35,000 | $370,000 | $436 | $913,081 |
| % Growth | -90.5% | 84,762.4% | -100% | – |
| Cost of Goods Sold | $110,250 | $130,250 | $110,250 | $101,178 |
| Gross Profit | -$75,250 | $239,750 | -$109,814 | $811,903 |
| % Margin | -215% | 64.8% | -25,186.7% | 88.9% |
| R&D Expenses | $320,653 | $387,332 | $461,645 | $340,567 |
| G&A Expenses | $72,977 | $76,162 | $102,464 | $99,690 |
| SG&A Expenses | $72,977 | $76,162 | $102,464 | $99,690 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,314 | -$1,206 | -$762 | -$1,882 |
| Operating Expenses | $391,316 | $462,288 | $563,347 | $438,375 |
| Operating Income | -$466,566 | -$222,538 | -$673,161 | $373,528 |
| % Margin | -1,333% | -60.1% | -154,394.7% | 40.9% |
| Other Income/Exp. Net | $103,901 | $71,816 | $22,661 | $6,003 |
| Pre-Tax Income | -$362,665 | -$150,722 | -$650,500 | $379,531 |
| Tax Expense | $3,587 | $2,888 | -$325 | $1,870 |
| Net Income | -$366,252 | -$153,610 | -$650,175 | $377,661 |
| % Margin | -1,046.4% | -41.5% | -149,122.7% | 41.4% |
| EPS | -4.34 | -1.94 | -8.36 | 4.97 |
| % Growth | -123.7% | 76.8% | -268.2% | – |
| EPS Diluted | -4.34 | -1.94 | -8.36 | 4.7 |
| Weighted Avg Shares Out | 84,359 | 79,221 | 77,747 | 75,949 |
| Weighted Avg Shares Out Dil | 84,359 | 79,221 | 77,747 | 80,393 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $19,259 | $19,837 | $24,172 | $17,953 |
| EBITDA | -$447,307 | -$202,701 | -$648,989 | $391,481 |
| % Margin | -1,278% | -54.8% | -148,850.7% | 42.9% |